An in vitro study of blood compatibility of vascular grafts made of bacterial cellulose in comparison with conventionally-used graft materials

Journal of Biomedical Materials Research - Part A

Volumn 97 A, Issue 1, 2011, Pages 52-58

  Fink, Helen ^a   Hong, Jaan ^b   Drotz, Kristoffer ^c   Risberg, Bo ^a   Sanchez, Javier ^b   Sellborn, Anders ^a  

^a SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

Bacterial cellulose; Blood compatibility; Chandler loop; Coagulation; Complement activation; ePTFE; PET

Indexed keywords

BACTERIOLOGY; BLOOD; CELLULOSE; COAGULATION; ETHYLENE; GRAFTING (CHEMICAL); MATERIALS; PLATELETS; POLYETHYLENE TEREPHTHALATES; POLYSACCHARIDES; TUBES (COMPONENTS);

BACTERIAL CELLULOSE; BLOOD COMPATIBILITY; CHANDLER LOOP; COMPLEMENT ACTIVATION; EPTFE; PET;

GRAFTS;

BACTERIAL CELLULOSE; BIOMATERIAL; CELLULOSE; COMPLEMENT COMPONENT C3; COMPLEMENT MEMBRANE ATTACK COMPLEX; HEPARIN; POLITEF; POLYETHYLENE TEREPHTHALATE; THROMBIN ANTITHROMBIN COMPLEX; UNCLASSIFIED DRUG; ANTITHROMBIN III; ANTITHROMBIN III-PROTEASE COMPLEX; COMPLEMENT COMPONENT C3A; PEPTIDE HYDROLASE;

ANTICOAGULATION; ARTICLE; BLOOD COMPATIBILITY; BLOOD SAMPLING; BLOOD VESSEL GRAFT; COMPLEMENT ACTIVATION; CONTROLLED STUDY; ENZYME IMMUNOASSAY; GLUCONACETOBACTER XYLINUS; HUMAN; IN VITRO STUDY; THROMBOCYTE; BLOOD CLOTTING; BLOOD VESSEL PROSTHESIS; COMPARATIVE STUDY; DRUG EFFECTS; MATERIALS TESTING; METABOLISM; PROCEDURES;

ANTITHROMBIN III; BLOOD COAGULATION; BLOOD PLATELETS; BLOOD VESSEL PROSTHESIS; CELLULOSE; COMPLEMENT ACTIVATION; COMPLEMENT C3A; COMPLEMENT MEMBRANE ATTACK COMPLEX; HEPARIN; HUMANS; MATERIALS TESTING; PEPTIDE HYDROLASES;

EID: 79951966689     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.33031     Document Type: Article

References (43)

1. Grunkemeier JM, Tsai WB, Horbett TA. Hemocompatibility of treated polystyrene substrates: Contact activation, platelet adhesion, and procoagulant activity of adherent platelets. J Biomed Mater Res 1998;41:657-670. (Pubitemid 28355451)
2. Hunt BJ, Parratt R, Cable M, Finch D, Yacoub M. Activation of coagulation and platelets is affected by the hydrophobicity of artificial surfaces. Blood Coagul Fibrinolysis 1997;8:223-231. (Pubitemid 27286582)
3. Boon GD. An overview of hemostasis. Toxicol Pathol 1993;21: 170-179. (Pubitemid 23241710)
4. Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344:1058-1066.
5. Walport MJ. Complement. Second of two parts. N Engl J Med 2001;344:1140-1144.
6. Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. The role of complement in biomaterial-induced inflammation. Mol Immunol 2007; 44:82-94. (Pubitemid 44647107)
7. Tang L, Liu L, Elwing HB. Complement activation and inflammation triggered by model biomaterial surfaces. J Biomed Mater Res 1998;41:333-340. (Pubitemid 28272492)
8. Kalltorp M, Askendal A, Thomsen P, Tengvall P. Inflammatory cell recruitment, distribution, and chemiluminescence response at IgG precoated- and thiol functionalized gold surfaces. J Biomed Mater Res 1999;47:251-259. (Pubitemid 29409745)
9. DeHeer DH, Engels JA, DeVries AS, Knapp RH, Beebe JD. In situ complement activation by polyethylene wear debris. J Biomed Mater Res 2001;54:12-19.
10. Bengtsson A, Svalander CT, Molne J, Rydberg L, Breimer ME. Extracorporeal ("ex vivo") connection of pig kidneys to humans. III. Studies of plasma complement activation and complement deposition in the kidney tissue. Xenotransplantation 1998;5: 176-183.
11. Andersson M, Andersson J, Sellborn A, Berglin M, Nilsson B, Elwing H. Quartz crystal microbalance-with dissipation monitoring (QCM-D) for real time measurements of blood coagulation density and immune complement activation on artificial surfaces. Biosens Bioelectron 2005;21:79-86. (Pubitemid 40828277)
12. Tiwari A, Cheng KS, Salacinski H, Hamilton G, Seifalian AM. Improving the patency of vascular bypass grafts: The role of suture materials and surgical techniques on reducing anastomotic compliance mismatch. Eur J Vasc Endovasc Surg 2003;25: 287-295. (Pubitemid 36531462)
13. McCullough JN, Abel RM, Rubenstein H. Polytetrafluoroethylene graft for spontaneous coronary dissection: 7-year follow-up. Ann Thorac Surg 1990;50:663-664. (Pubitemid 20360836)
14. Emery RW, Petersen R, Baumgard C, Nicoloff DM. First clinical use of the Possis synthetic coronary graft. J Card Surg 1993;8: 439-442. (Pubitemid 23212468)
15. Bodin A, Backdahl H, Fink H, Gustafsson L, Risberg B, Gatenholm P. Influence of cultivation conditions on mechanical and morphological properties of bacterial cellulose tubes. Biotechnol Bioeng 2007;97:425-434. (Pubitemid 46852936)
16. Backdahl H, Helenius G, Bodin A, Nannmark U, Johansson BR, Risberg B, Gatenholm P. Mechanical properties of bacterial cellulose and interactions with smooth muscle cells. Biomaterials 2006;27:2141-2149. (Pubitemid 41759508)
17. Helenius G, Backdahl H, Bodin A, Nannmark U, Gatenholm P, Risberg B. In vivo biocompatibility of bacterial cellulose. J Biomed Mater Res A 2006;76:431-438.
18. Thomas S. A review of the physical, biological and clinical properties of a bacterial cellulose wound dressing. J Wound Care 2008;17:349-352.
19. Wippermann J, Schumann D, Klemm D, Kosmehl H, Salehi-Gelani S, Wahlers T. Preliminary results of small arterial substitute performed with a new cylindrical biomaterial composed of bacterial cellulose. Eur J Vasc Endovasc Surg 2009;37:592-596.
20. Bodin A, Backdahl H, Helenius G, Gustafsson L, Risberg B, Gatenholm P. Bacterial cellulose as scaffold for tissue engineering. Abstr Pap Am Chem Soc 2005;229:U297-U297.
21. Johnell M, Larsson R, Siegbahn A. The influence of different heparin surface concentrations and antithrombin-binding capacity on inflammation and coagulation. Biomaterials 2005;26:1731-1739. (Pubitemid 39575316)
22. Gong J, Larsson R, Ekdahl KN, Mollnes TE, Nilsson U, Nilsson B. Tubing loops as a model for cardiopulmonary bypass circuits: Both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vitro model. J Clin Immunol 1996; 16:222-229. (Pubitemid 26249187)
23. Nilsson Ekdahl K, Nilsson B, Pekna M, Nilsson UR. Generation of iC3 at the interface between blood and gas. Scand J Immunol 1992;35:85-91.
24. Mollnes TE, Lea T, Harboe M, Tschopp J. Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma. Scand J Immunol 1985;22:183-195.
25. Larsson R, Elgue G, Larsson A, Ekdahl KN, Nilsson UR, Nilsson B. Inhibition of complement activation by soluble recombinant CR1 under conditions resembling those in a cardiopulmonary circuit: Reduced up-regulation of CD11b and complete abrogation of binding of PMNs to the biomaterial surface. Immunopharmacology 1997;38:119-127. (Pubitemid 28049972)
26. Georgopoulos LJ, Elgue G, Sanchez J, Dussupt V, Magotti P, Lambris JD, Totterman TH, Maitland NJ, Nilsson B. Preclinical evaluation of innate immunity to baculovirus gene therapy vectors in whole human blood. Mol Immunol 2009;46:2911-2917.
27. Cabric S, Eich T, Sanchez J, Nilsson B, Korsgren O, Larsson R. A new method for incorporating functional heparin onto the surface of islets of Langerhans. Tissue Eng Part C Methods 2008;14: 141-147. (Pubitemid 351838707)
28. Mangsbo SM, Sanchez J, Anger K, Lambris JD, Ekdahl KN, Loskog AS, Nilsson B, Totterman TH. Complement activation by CpG in a human whole blood loop system: Mechanisms and immunomodulatory effects. J Immunol 2009;183:6724-6732.
29. Santos MT, Valles J, Marcus AJ, Safier LB, Broekman MJ, Islam N, Ullman HL, Eiroa AM, Aznar J. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment. J Clin Invest 1991;87:571-580.
30. Fink H, Faxalv L, Molnar GF, Drotz K, Risberg B, Lindahl TL, Sellborn A. Real-time measurements of coagulation on bacterial cellulose and conventional vascular graft materials. Acta Biomater 2010;6: 1125-1130.
31. Katritsis D, Kaiktsis L, Chaniotis A, Pantos J, Efstathopoulos EP, Marmarelis V. Wall shear stress: Theoretical considerations and methods of measurement. Prog Cardiovasc Dis 2007;49: 307-329. (Pubitemid 46295438)
32. Frank RD, Weber J, Dresbach H, Thelen H, Weiss C, Floege J. Role of contact system activation in hemodialyzer-induced thrombogenicity. Kidney Int 2001;60:1972-1981. (Pubitemid 33000004)
33. Fushimi F, Nakayama M, Nishimura K, Hiyoshi T. Platelet adhesion, contact phase coagulation activation, and C5a generation of polyethylene glycol acid-grafted high flux cellulosic membrane with varieties of grafting amounts. Artif Organs 1998;22:821-826. (Pubitemid 28471271)
34. Hamad OA, Ekdahl KN, Nilsson PH, Andersson J, Magotti P, Lambris JD, Nilsson B. Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets. J Thromb Haemost 2008;6:1413-1421. (Pubitemid 352016323)
35. Peerschke EI, Yin W, Grigg SE, Ghebrehiwet B. Blood platelets activate the classical pathway of human complement. J Thromb Haemost 2006;4:2035-2042. (Pubitemid 44226786)
36. Gyongyossy-Issa MI, McLeod E, Devine DV. Complement activation in platelet concentrates is surface-dependent and modulated by the platelets. J Lab Clin Med 1994;123:859-868. (Pubitemid 2103602)
37. Kim HI, Yu JE, Lee SY, Sul AY, Jang MS, Rashid MA, Park SG, Kim SJ, Park CG, Kim JH, Park KS. The effect of composite pig islet-human endothelial cell grafts on the instant blood-mediated inflammatory reaction. Cell Transplant 2009;18:31-37.
38. Fernandez HN, Hugli TE. Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a. J Biol Chem 1978;253:6955-6964. (Pubitemid 9068505)
39. Nordahl EA, Rydengard V, Nyberg P, Nitsche DP, Morgelin M, Malmsten M, Bjorck L, Schmidtchen A. Activation of the complement system generates antibacterial peptides. Proc Natl Acad Sci USA 2004;101:16879-16884. (Pubitemid 39601332)
40. Ferraz N, Nilsson B, Hong J, Karlsson Ott M. Nanoporesize affects complement activation. J Biomed Mater Res A 2008;87:575-581.
41. Andersson J, Sanchez J, Ekdahl KN, Elgue G, Nilsson B, Larsson R. Optimal heparin surface concentration and antithrombin binding capacity as evaluated with human non-anticoagulated blood in vitro. J Biomed Mater Res A 2003;67:458-466. (Pubitemid 37522451)
42. Moen O, Hogasen K, Fosse E, Dregelid E, Brockmeier V, Venge P, Harboe M, Mollnes TE. Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1997;63:105-111. (Pubitemid 27039043)
43. Lappegard KT, Fung M, Bergseth G, Riesenfeld J, Mollnes TE. Artificial surface-induced cytokine synthesis: Effect of heparin coating and complement inhibition. Ann Thorac Surg 2004;78: 38-44; discussion 44-45.